Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (NASDAQ: GILD) announced the FDA accepted its NDA for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) and granted priority review with a PDUFA action date of August 27, 2026.
Phase 3 ARTISTRY-1 and ARTISTRY-2 showed comparable Week 48 maintenance of virologic suppression and generally favorable tolerability; BIC/LEN remains investigational and not approved.
Gilead Sciences (Nasdaq: GILD) completed its acquisition of Arcellx (Nasdaq: ACLX) on April 28, 2026, buying Arcellx for $115 cash per share plus one $5 CVR, implying approximately $7.8 billion equity value.
The CVR pays if cumulative global net sales of anito-cel reach $6.0 billion through 2029. Arcellx becomes a Gilead subsidiary and its common stock will be delisted. Gilead expects 2026 diluted EPS to decline by $5.57–$5.67 and forecasts modest dilution in 2026–2027, with accretion in 2028+ subject to FDA approval of anito-cel.
Gilead Sciences (Nasdaq: GILD) will release its first quarter 2026 financial results on Thursday, May 7, 2026 after the market close. Management will host a live webcast at 4:30 p.m. ET that day to discuss results and provide a business update. The webcast will be archived on Gilead's investor site for one year.
Gilead (Nasdaq: GILD) said all required regulatory approvals for its acquisition of Arcellx have been obtained and extended the tender offer deadline to 5:00 p.m. ET on April 27, 2026. The offer remains $115.00 cash per share plus one CVR potentially worth $5.00 payable March 31, 2030, if cumulative worldwide sales of anito-cel exceed $6.0 billion by December 31, 2029. As of 4:00 p.m. ET on April 16, 2026, ~10,271,823 shares (about 17.5%) were validly tendered. The transaction still requires customary closing conditions including a majority of outstanding Arcellx shares being tendered.
Gilead (Nasdaq: GILD) said PEPFAR and The Global Fund will further invest to expand access to its twice-yearly injectable HIV prevention medicine lenacapavir, reaching an additional 1 million people and bringing total commitment to up to 3 million people through 2028.
The company said lenacapavir shipments began in late 2025, Gilead is supplying doses at no profit to these partners, and broad generic rollout is expected in 2027 via voluntary licenses with six manufacturers.
Tempus (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead (NASDAQ:GILD) to advance oncology R&D using real-world evidence and AI. The agreement gives Gilead enterprise-wide access to Tempus' Lens platform, broader multimodal datasets across multiple indications, and dedicated Tempus analytical services.
This collaboration targets trial design, indication selection, biomarker strategy, and health outcomes analysis to inform clinical decision-making and support oncology pipeline development.
Gilead (Nasdaq: GILD) agreed to acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in contingent milestones, expanding Gilead’s antibody-drug conjugate (ADC) capabilities and oncology pipeline. The deal adds lead candidate TUB-040 (NaPi2b TOPO1i ADC, Phase 1b/2) and TUB-030.
Gilead plans to finance the transaction with cash on hand and senior unsecured notes; closing is expected in Q2 2026 and is subject to customary conditions.
Gilead (Nasdaq: GILD) extended its tender offer for Arcellx common stock to 5:00 p.m. ET on April 24, 2026. The offer remains $115.00 cash per share plus one CVR entitling holders to a possible $5.00 payment if anito-cel cumulative worldwide sales exceed $6.0 billion by December 31, 2029.
As of 5:00 p.m. ET on March 31, 2026, approximately 4,389,763 shares (about 7.5%) were validly tendered. The transaction is expected to close in Q2 2026, subject to customary conditions including majority tender and regulatory approvals.
Gilead Sciences (Nasdaq: GILD) agreed to acquire Ouro Medicines for $1,675 million upfront plus up to $500 million in contingent milestones, adding OM336 (gamgertamig), a clinical‑stage BCMAxCD3 T cell engager targeting autoimmune diseases.
Gilead expects OM336 to enter registrational studies in 2027, and is in advanced talks with Galapagos for a collaboration where Galapagos funds 50% of upfront and development costs and receives 20%-23% royalties.
Gilead Foundation (Nasdaq: GILD) announced a $12 million grant program funding 33 community organizations across 14 states and the District of Columbia through a two-year Community Health Worker (CHW) HIV prevention initiative. The effort expands CHW-led prevention, training, screening, navigation, and culturally aligned outreach prioritizing communities most impacted by HIV.
The grants support integrated screening for HIV, STIs, mental health and substance use, peer navigation, promotores models, pharmacy training, and youth-focused programming to strengthen local prevention networks and reduce stigma.